The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The TADs are followed by a PRD (AA residues 62–94) that includes five PXXP (P: proline; X: any AA) motifs.15 This region plays a critical role in promoting cell cycle arrest and p53-associated death.24,25”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UniProt: the universal protein knowledgebase in 2021
The UniProt Consortium, Bateman, A., Martin, M.-J., Orchard, S., Magrane, M., Agivetova, R., Ahmad, S., Alpi, E., Bowler-Barnett, E. H., Britto, R., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1100 · Cited by 6,372
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“DATABASES OF TP53 MUTATIONS IN THE PROLINE DOMAIN Five different databases, IARC R20 (N= 21,732) [20], TCGA (N= 2764) [21], MSK-IMPACT (N= 16,244) [22], cBio-Genie (N= 17,817) [23], and COSMIC (N= 33,176) [24], with the Tp53 gene sequenced from cancers (N= 73,857 sequences) were screened for somatic Tp53 missense muta…”
BackgroundAACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Toward a Shared Vision for Cancer Genomic Data
Grossman, R. L., Heath, A. P., Ferretti, V., Varmus, H. E., Lowy, D. R., Kibbe, W. A., & Staudt, L. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1607591 · Cited by 1,680 · cited 1×
“DATABASES OF TP53 MUTATIONS IN THE PROLINE DOMAIN Five different databases, IARC R20 (N= 21,732) [20], TCGA (N= 2764) [21], MSK-IMPACT (N= 16,244) [22], cBio-Genie (N= 17,817) [23], and COSMIC (N= 33,176) [24], with the Tp53 gene sequenced from cancers (N= 73,857 sequences) were screened for somatic Tp53 missense muta…”
BackgroundBouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730
Toledo, F., Krummel, K. A., Lee, C. J., Liu, C.-W., Rodewald, L.-W., Tang, M., & Wahl, G. M. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.014 · Cited by 199
Zeron-Medina, J., Wang, X., Repapi, E., Campbell, M. R., Su, D., Castro-Giner, F., Davies, B., Peterse, E. F. P., Sacilotto, N., Walker, G. J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.017 · Cited by 118 · cited 2×
“There is abundant evidence that the codon 72 polymorphism in the Tp53 gene, its protein, and the pathway influences pigmentation in response to UV light exposure, altitude, as well as an association with transcription levels of the KIT ligand that is involved with neural crest migration and melanocyte distribution in…”
Background
Research works printed but not linked: 31
- Levine AJ p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. (2020). https://doi.org/10.1038/s41568-020-0262-1. · DOI · Paper page
- Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 1994;8:1235–1246. · DOI · Paper page
- Mello SS, Attardi LD. Deciphering p53 signaling in tumor suppression. Curr Opin Cell Biol. 2018;51:65–72. https://doi.org/10.1016/j.ceb.2017.11.005. · DOI · Paper page
- Walker KK, Levine AJ. Identification of a novel p53 functional domain which is necessary for efficient growth suppression. Proc Natl Acad Sci, USA. 1996;93:15335–15340. · DOI · Paper page
- Baptiste N, Friedlander P, Chen X, Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene. 2002;21:9–21. · DOI
- Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 2018;25:154–160. · DOI · Paper page
- Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 1995;267:14987–1502. · DOI · Paper page
- Zhu J, Dou Z, Sammons MA, Levine AJ, Berger SL. Lysine methylation represses p53 activity in teratocarcinoma cancer cells. Proc Natl Acad Sci USA. 2016;113:9822–9827. https://doi.org/10.1073/pnas.1610387113. · DOI
- Beckman G, Birgander R, Själander A, Saha N, Holmberg PA, Kivelä A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered. 1994;44:266–70. https://doi.org/10.1159/000154228. · DOI · Paper page
- Guha T, Malkin D. Inherited TP53 mutations and the li-fraumeni syndrome. Cold Spring Harb Perspect Med. 2017;7:a026187 https://doi.org/10.1101/cshperspect.a026187. · DOI · Paper page
- Zilfou JT, Hoffman WH, Sank M, George DL, Murphy M. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol Cell Biol. 2001;21:3974–85. https://doi.org/10.1128/MCB.21.12.3974-3985.2001. · DOI
- Berger M, Sionov RV, Levine AJ, Haupt Y. A role for the polyproline domain of p53 in its regulation by Mdm2. J Biol Chem. 2001;276.6:3785–3790. · DOI
- Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, et al. Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Canc Res. 2005;11:7328–7333. https://doi.org/10.1158/1078-0432.CCR-05-0507 · DOI
- Lee MG, Han J, Jeong SI, Her NG, Lee JH, Ha TK, et al. XAF1 directs apoptotic switch of p53 signaling through activation of HIPK2 and ZNF313. Proc Natl Acad Sci USA 2014;111:15532–7. https://doi.org/10.1073/pnas.1411746111. · DOI
- Barnoud T, Parris JLD, Murphy M. Common genetic variants in the Tp53 pathway and their impact on cancer. Jour Mol Cell Biol. 2019;11:578–585. · DOI
- Shi H, Tan SJ, Zhong H, Hu W, Levine A, Xiao CJ, et al. Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet. 2009;84:534–41. https://doi.org/10.1016/j.ajhg.2009.03.009. · DOI
- Pinto EM, Figueiredo BC, Chen W, Galvao HCR, Formiga MN, Fragoso MCBV, et al. XAF1 as a modifier of p53 function and cancer susceptibility. Sci Adv. 2020;6:eaba3231 https://doi.org/10.1126/sciadv.aba3231. · DOI
- Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci. 2003;100:8424–9. · DOI · Paper page
- Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Canc Res. 1991;51:5520–5.
- Kawamura M, Kikuchi A, Kobayashi S, Hanada R, Yamamoto K, Horibe K, et al. Mutations of the p53 and ras genes in childhood t (1; 19)-acute lymphoblastic leukemia. Blood. 1995;85:2546–52. · DOI
- Toguchida J, Yamaguchi T, Dayton SH, Beaughamp RL, Herrera GE, Ishizaki K, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med. 1992;326:1301–8. · DOI · Paper page
- Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 2007;9:R34 https://doi.org/10.1186/bcr1682. · DOI
- Weng Z, Rickles RJ, Feng S, Richard S, Shaw AS, Schreiber SL et al. Structure-function analysis of SH3 domains: SH3 binding specificity altered by single amino acid substitutions. Mol Cell Biol. :5627–34 (1995). https://doi.org/10.1128/MCB.15.10.5627. · DOI
- Natan E, Baloglu C, Pagel K, Freund SM, Morgner N, Robinson CV, et al. Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer. J Mol Bio. 2011;409:358–68. · DOI
- Berger M, Stahl N, Del Sal G, Haupt Y. Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol Cell Biol. 2005;25:5380–8. https://doi.org/10.1128/MCB.25.13.5380-5388.2005. · DOI
- D’Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol. 2002;4:11–9. https://doi.org/10.1038/ncb714. · DOI · Paper page
- Dornan D, Shimizu H, Burch L, Smith AJ, Hupp TR. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol Cell Biol. 2003;23:8846–8861. · DOI
- Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, et al. Identification of XAF-1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol. 2001;3:128–133. https://doi.org/10.1038/3590550237. · doi:10.1038/3590550237
- Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94–101. https://doi.org/10.1038/s41586-020-1943-3. · DOI · Paper page
- Lunter G, Hein J. A nucleotide substitution model with nearest-neighbour interactions. Bioinformatics. 2004;20:i216–i223. · DOI
- Belyi VA, Ak P, Markert E, Wang H, Hu W, Puzio-Kuter A, et al. The origins and evolution of the P53 family of genes. Cold Spring Harb Perspect Biol. 2010;2:a001198. https://doi.org/10.1101/cshperspect.a001198. · DOI · Paper page
Cited by
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Deciphering the ghost proteome in ovarian cancer cells by deep proteogenomic characterization
Garcia-del Rio, D. F., Derhourhi, M., Bonnefond, A., Leblanc, S., Guilloy, N., Roucou, X., Eyckerman, S., Gevaert, K., Salzet, M., & Cardon, T. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07046-1 · Cited by 7
Metadata
- Authors
- Hoyos, D., Greenbaum, B., & Levine, A. J.
- Venue
- Cell Death & Differentiation
- Published
- 2022-04-05
- Volume
- 29
- Issue
- 5
- Pages
- 938-945
- ISSN
- 1350-9047
- 1476-5403
- Cited by
- 48
- References
- 8
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Funders
- U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P01CA087497-20)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein. https://app.cochat.ai/papers/10.1038/s41418-022-00980-7
- The paper
- Hoyos, D., Greenbaum, B., & Levine, A. J. (2022). The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein. Cell Death & Differentiation. https://doi.org/10.1038/s41418-022-00980-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.